Cancer Treatment Registry




Login


Gleevec

Category: Chemotherapy

Other Names: Imatinib

Imatinib is used in chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GISTs) and a number of other malignancies. One study demonstrated that Imatinib mesylate was effective in patients with systemic mastocytosis, including those who had the D816V mutation in c-Kit. Experience has shown, however, that imatinib is much less effective in patients with this mutation, and patients with the mutation comprise nearly 90% of cases of mastocytosis. Early clinical trials also show its potential for treatment of hypereosinophilic syndrome and dermatofibrosarcoma protuberans.

The Food and Drug Administration has approved imatinib as first-line treatment for Chronic Myelogenous Leukemia. Imatinib has passed through Phase III trials for CML, and has been shown to be more effective than the previous standard treatment of α-interferon and cytarabine. Although the long-term side effects of imatinib have not yet been ascertained, research suggests that it is generally very well tolerated (eg. liver toxicity was much less than predicted). Broadly, side effects such as edema, nausea, rash and musculoskeletal pain are common but mild.

Severe congestive cardiac failure is an uncommon but recognised side effect of imatinib and mice treated with large doses of imatinib show toxic damage to their myocardium.

Google it: Gleevec

Add A Comment


NEWS

Newest Member   User name: JohnD
  Location: Add Other Location     
  Washington, 98382 Age: 69

Newest Treatment MSQ Nutritional Therapy
Type: Nutritional

Most Viewed IP6
Type: Nutritional

Most Used Treatment Chemotherapy
Type: Chemotherapy




Home View-Patients View-Treatments View-Statistics View-Doctors Sitemap Sponsors Contact